CSIMarket
 
I mab  (IMAB)
Other Ticker:  
 
 
Price: $1.8100 $-0.05 -2.688%
Day's High: $1.8507 Week Perf: -1.09 %
Day's Low: $ 1.73 30 Day Perf: 2.26 %
Volume (M): 342 52 Wk High: $ 3.88
Volume (M$): $ 619 52 Wk Avg: $2.24
Open: $1.74 52 Wk Low: $1.16



 Market Capitalization (Millions $) 344
 Shares Outstanding (Millions) 190
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -364
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 7

I Mab
I mab, also known as immunomodulatory antibody, is a type of monoclonal antibody that is used in immunotherapy for the treatment of certain diseases. It acts by targeting specific proteins on cells of the immune system, thereby modulating immune responses. This can be done by either enhancing or suppressing the activity of immune cells, depending on the specific disease being treated. I mab has shown promising results in treating various conditions such as cancer, autoimmune disorders, and inflammatory diseases. It is typically administered intravenously and may be used in combination with other therapies to improve treatment outcomes.


   Company Address: 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai 200124
   Company Phone Number: 6057-8000   Stock Exchange / Ticker: NASDAQ IMAB
   IMAB is expected to report next financial results on April 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eyenovia Inc

The Major Pharmaceutical Preparations company released Revenue of $0.002589 million, in thefourth quarter of 2023 financial report

EYEN proclaimed $0.002589 million, in Revenue in the October to December 31 2023 fiscal time-frame.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Following the leaders in the Major Pharmaceutical Preparations industry, some lesser known companies are publishing the numbers. ATXI told it has clinched operating loss of $-2.12 million, for the fourth quarter of 2023.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.






 

I Mab's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com